255 filings
Page 3 of 13
8-K
qfuj n2vc
10 Mar 22
Results of Operations and Financial Condition
4:09pm
424B5
h5bagze49r6p034
1 Mar 22
Prospectus supplement for primary offering
5:12pm
8-K
qoyyqau gh
1 Mar 22
Entry into a Material Definitive Agreement
4:41pm
8-K
hlt7h85ida9ye
1 Mar 22
Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update
12:00am
8-K
vw0tex6dxx1r
12 Jan 22
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone
8:04am
8-K
vgao3daebu2xx
1 Dec 21
Entry into a Material Definitive Agreement
4:02pm
8-K
eze8sepjdyqdmgt8iu3c
10 Nov 21
Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:14pm
424B5
474isyn69 pw4ecw
6 Oct 21
Prospectus supplement for primary offering
5:05pm
8-K
5g4yrv0f nhv2q1n0i
6 Oct 21
Other Events
4:50pm
FWP
y77ejeiu
5 Oct 21
Free writing prospectus
4:34pm
424B5
zk39dx 85b2i88
4 Oct 21
Prospectus supplement for primary offering
5:27pm
S-3ASR
isvtz8r lju
4 Oct 21
Automatic shelf registration
4:02pm
8-K
piifnec ap8qosv58
4 Oct 21
Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2b ‘X-TOLE’ Clinical Trial of XEN1101 for the Treatment of Focal Epilepsy
7:03am
8-K
t4t4z
8 Sep 21
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $10.0 Million Regulatory Milestone
8:32am
8-K
qguyzc7i
23 Aug 21
Xenon Pharmaceuticals Strengthens Leadership Team with Appointment of Dr. Christopher Kenney as Chief Medical Officer
8:33am
8-K
svb3w 3f5sg6
11 Aug 21
Xenon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
4:16pm
8-K
8aerp99fv23z5xdcpfq
3 Jun 21
Submission of Matters to a Vote of Security Holders
5:25pm